Shots:

• The FDA decision to lift the hold of P-I clinical trial for RP-A501 is based on the modification of the trial protocol and other supporting documents with revised guidelines for patient selection and management
• The FDA allows the company to restart the patient enrolment. Additionally- the company is expected to initiate the dosing of the low-dose pediatric patients in Q3’21
• The P-I trial evaluates the safety and tolerability of RP-A501 therapy (IV infusion) in both pediatric and young adult male patients. The company will report the updated data from the low-dose and higher-dose young adult cohorts in Q4’21

| Ref: Businesswire | Image: Businesswire